CEOs, Senior Executives Highlight Strategies, M&A, and Expansions at DCAT Week
By

Chief executive officers and senior executives from DCAT member companies provided key updates on strategy, mergers and acquisitions, and expansions at the DCAT Member Company Announcement Forum held during DCAT Week in mid-March.

The executives highlighted key company activity impacting the pharmaceutical manufacturing value chain. SCHOTT, Catalent, Thermo Fisher Scientific, Cambrex, Lonza, BSP Pharmaceuticals, Servier CDMO, Selkirk Pharma, Seqens, Cerbios-Pharma, and ACG were among the companies taking the podium to provide their latest developments (see announcements below).

SCHOTT Plans $1-Billion Expansion in Pharma Packaging

Catalent Investing $214 Million to Expand Biologics Capabilities; Invests in Oral Delivery Capabilities

Thermo Fisher Scientific Investing $150 Million in Sterile Injectables Development and Manufacturing

Cambrex Updates Integration of Halo Pharma and Avista Pharma; Expands Small-Molecule API Mfg

Lonza Updates $100-Million Expansion for High-Potency APIs and Small-Molecule Mfg

BSP To Add High-Containment Capacity for Conjugation and Injectable Drug Products

Servier CDMO Invests $55 Million for Bioproduction and $7 Million for Industrial Prep Chromatography

New CDMO Selkirk Pharma Investing $30 Million in Aseptic Fill–Finish Facility

Seqens Investing $30 Million to Expand High-Potency Manufacturing

Cerbios-Pharma Investing in New High-Potency API Production Line and Conjugation Suite

ACG Expands Capsule Production in Brazil, India, and Croatia

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The CDMO/CMO Report: Cell and Gene Therapies
By

By
Although a niche market, cell and gene therapy development and manufacturing continues to be an active area of investment by CDMOs/CMOs. Facing limited industry capacity, both pure-play CDMOs and bio/pharma companies with CDMO services continue to expand. A roundup of the latest expansions.

Pharma Innovation: AI in Drug Manufacturing
By

By
What is the potential of artificial intelligence (AI) in pharmaceutical manufacturing and what regulatory considerations come into play, including between CDMOs/CMOs and sponsor companies? The FDA has issued a discussion paper to highlight key issues and is seeking input from the industry.

Pharma Industry Outlook: What Lies Ahead?
By

By
With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

ROI in Pharma R&D Falls in Post-Pandemic Market
By

By
A recent analysis by the management consultancy firm, Deloitte, shows that the bio/pharma industry’s return on investment (ROI) in R&D has fallen in the post-pandemic market. Projected ROI in pharma R&D in 2022 fell to 1.2%, the lowest ROI observed in the 13 years since the firm has conducted the study.